Reglan Tardive Dyskinesia Settlement: Criteria Explained

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Targeted Risk Communication

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad context, discussions of pharmaceutical therapies have historically emphasized benefits and standard precautions, often framed within a general wellness perspective. As this informational heritage evolved, it increasingly recognized the importance of detailing specific risks associated with long-term medication use, particularly for drugs affecting neurological function. This shift from broad health guidance to more targeted risk communication reflects a growing awareness that certain patient populations face distinct exposure scenarios. In the domain of mass production, where repetitive tasks and extended work shifts are common, the occupational context introduces unique considerations. Workers may experience prolonged exposure to medications or environmental factors that amplify health risks. The transition from general health information to occupational exposure concern is particularly relevant when examining the relationship between Reglan use and the development of tardive dyskinesia. Understanding how workplace conditions intersect with pharmaceutical exposure requires careful analysis of duration, dosage, and individual susceptibility factors that may differ from general patient populations.

Find Out If You Qualify for Compensation →

Reglan and Tardive Dyskinesia: A Medical Overview

Reglan (metoclopramide) is a dopamine receptor blocking agent prescribed primarily for diabetic gastroparesis and symptomatic gastroesophageal reflux. Its use carries a well-documented risk of tardive dyskinesia (TD), a potentially irreversible hyperkinetic movement disorder. The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further specifies that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for signs and symptoms of TD is required (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, often disfiguring movements of the face, tongue, trunk, or extremities. The condition is caused by exposure to dopamine receptor blocking agents, including metoclopramide (https://pubmed.ncbi.nlm.nih.gov/29433808/). Although TD was initially associated most commonly with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide (https://pubmed.ncbi.nlm.nih.gov/29433808/). The clinical presentation can range from mild, subtle movements to severe, disabling dyskinesias that interfere with daily function. Diagnosis is based on clinical examination and history of exposure to a dopamine receptor blocking agent. The FDA-approved labeling notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism and Risk Factors for Reglan-Induced Tardive Dyskinesia

The mechanistic pathway linking Reglan to TD involves chronic blockade of dopamine D2 receptors in the striatum, leading to upregulation of dopamine receptors and subsequent supersensitivity. This dysregulation of dopaminergic signaling is thought to underlie the development of involuntary movements. The risk of TD from metoclopramide is considered low, with data indicating a rate of approximately 0.1% per 1000 patient-years, which is far below earlier estimates of 1% to 10% suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, certain populations are at higher risk, including elderly females, diabetics, patients with liver or kidney failure, and those receiving concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). The risk increases with longer treatment duration and higher cumulative doses, as emphasized in the boxed warning. Regarding the adequacy of warnings, the FDA has required a boxed warning for Reglan since 2009, clearly stating the risk of TD and the need for short-term use. The warning also advises immediate discontinuation of Reglan if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, cases of TD continue to occur, often in patients who have used Reglan for extended periods beyond the recommended 12-week limit. This has led to litigation by affected patients alleging inadequate warnings or failure to monitor for TD.

Settlement Criteria for Reglan-Induced Tardive Dyskinesia

Settlement-related considerations for patients with Reglan-induced TD typically involve demonstrating that the drug was used for a duration exceeding the recommended maximum, that the patient developed TD as a result, and that the manufacturer failed to provide adequate warnings or instructions for monitoring. The timeline between exposure and documented harm is critical: TD often develops after months or years of continuous use, and symptoms may persist or become permanent even after discontinuation. Patients seeking settlement must establish a clear causal link between Reglan use and the onset of TD, supported by medical records documenting the duration of treatment and the emergence of symptoms. The availability of FDA-approved treatments for TD, such as VMAT2 inhibitors, may also be relevant to settlement considerations, as these therapies can manage symptoms but do not reverse the underlying condition (https://pubmed.ncbi.nlm.nih.gov/29433808/). In summary, Reglan carries a known risk of tardive dyskinesia, with the risk increasing with longer use and higher cumulative doses. The FDA has mandated strong warnings, but cases of TD continue to arise, particularly in high-risk populations. Patients who develop TD after prolonged Reglan use may have grounds for settlement, provided they can document the exposure timeline and the resulting harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA boxed warning for Reglan regarding tardive dyskinesia?

The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), and that the risk increases with duration of treatment and total cumulative dosage. The warning also specifies that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the key criteria for a Reglan tardive dyskinesia settlement?

Key criteria typically include demonstrating that Reglan was used for a duration exceeding the recommended maximum (usually 12 weeks), that the patient developed tardive dyskinesia as a result, and that the manufacturer failed to provide adequate warnings or instructions for monitoring. Medical records documenting the treatment duration and emergence of symptoms are essential to establish a causal link.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.